CORE Biomedicine$21M
Precision cancer medicines targeting the biological programs that define cancer-cell identity and sustain tumour growth.
UTokyo Innovation Platform Co., Elikon Venture
Startup Funding News
New startup rounds, lead investors and the businesses behind the funding.
5 rounds · $544.6M disclosed · $55M median
| Company | Amount | Stage / sector | Lead investor | Announced |
|---|---|---|---|---|
| CORE Biomedicine Precision cancer medicines targeting the biological programs that define cancer-cell identity and sustain tumour growth. | $21M | Series A Cancer therapeutics | UTokyo Innovation Platform Co., Elikon Venture | |
| Chai Discovery AI models and software that help pharmaceutical researchers design antibodies and other molecules for difficult drug targets. | $400M | Series C+ Drug discovery | Index Ventures | |
| Drug Farm Uses genetics and AI to identify drug targets and develop treatments for immune, metabolic and infectious diseases. | $55M | Series C+ Drug discovery | Shanghai Pudong Leading Area Investment Center, Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise | |
| Engine Biosciences Engine Biosciences combines machine learning with experimental genetics to identify drug targets and biomarkers for precision cancer medicines. | $13.6M | Undisclosed Biotech | — | |
| Think Bioscience Drug-discovery technology that uses synthetic biology to find binding pockets on proteins that have been difficult to target with small molecules. | $55M | Series A Drug discovery | Regeneron Ventures, Innovation Endeavors, Janus Henderson Investors |
Chai Discovery$400M
AI models and software that help pharmaceutical researchers design antibodies and other molecules for difficult drug targets.
Index Ventures
Drug Farm$55M
Uses genetics and AI to identify drug targets and develop treatments for immune, metabolic and infectious diseases.
Shanghai Pudong Leading Area Investment Center, Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise
Engine Biosciences$13.6M
Engine Biosciences combines machine learning with experimental genetics to identify drug targets and biomarkers for precision cancer medicines.
Think Bioscience$55M
Drug-discovery technology that uses synthetic biology to find binding pockets on proteins that have been difficult to target with small molecules.
Regeneron Ventures, Innovation Endeavors, Janus Henderson Investors
02 / Perspective
Reports & briefings
monthly briefing
September 2026 Startup Funding Report
77 sourced rounds, with company profiles and participating investors.
weekly briefing
Sep 21 – 27, 2026 Startup Funding Weekly
27 sourced rounds, with company profiles and participating investors.
weekly briefing
Sep 14 – 20, 2026 Startup Funding Weekly
5 sourced rounds, with company profiles and participating investors.
03 / Investors
Active investors
| Investor | Rounds | Led | Recent investments |
|---|---|---|---|
| 01Y Combinator | 27 | 2 | SpottConveo |
| 02Lightspeed Venture Partners | 24 | 6 | Temporal TechnologiesNeko Health |
| 03Index Ventures | 22 | 8 | Temporal TechnologiesMistral AI |
| 04Accel | 22 | 7 | ArmadinEma |